Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
MyMD Pharmaceuticals, Inc. (AKER) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023"
08/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application for Phase 2 Study of oral TNF-α inhibitor MYMD-1 ® in Rheumatoid Arthritis"
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Operator"
08/01/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/14/2023 8-K Other Events  Interactive Data
06/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Third AMENDMENT TO EMPLOYMENT AGREEMENT"
03/22/2023 8-K Other Events  Interactive Data
03/20/2023 8-K Quarterly results
03/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls"
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Announces U.S. Drug Enforcement Administration Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical"
02/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting"
02/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals, Inc., Registration Statement on Form S-3",
"MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 601 Baltimore, MD 21205"
02/03/2023 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/20/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan"
08/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MYMD PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN PATENT OFFICE FOR SUPERA-CBD™ COMPOUND"
08/17/2022 8-K Quarterly results
08/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Data Showing MyMD Pharmaceuticals’ MYMD-1 May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences"
07/26/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
04/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis"
02/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan"
02/08/2022 8-K Quarterly results
01/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia"
12/29/2021 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
12/03/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy